MedTrace Logo

A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

NCT01067859 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2015-10-08

No results posted yet for this study

Summary

A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.

Conditions

  • Acute Heart Failure

Interventions

DRUG

Cinaciguat (BAY58-2667)

Infusion of 25 µg/h during 48 hours

DRUG

Cinaciguat (BAY58-2667)

Infusion of 10 µg/h during 48 hours

DRUG

Placebo

Infusion of placebo during 48 hours

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-09-30
Completion
2010-11-30

Countries

  • United States
  • Argentina
  • Austria
  • Belgium
  • France
  • Germany
  • Ireland
  • Mexico
  • Philippines

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01067859 on ClinicalTrials.gov